Doctors say it's hard to overstate the importance of this study, and what it means for curbing this problem, which is growing because of the obesity epidemic.
The study tested the drug Invokana (in-vo-KAHN-ah) in people with Type 2 diabetes who were already getting standard treatments. Invokana lowered by 30% the risk of kidney failure, the need for dialysis or a kidney transplant or some other problems.
Results were discussed Sunday at a medical meeting in Australia and published by the New England Journal of Medicine.